ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,930.85
      1.09%
      US Tech 100
      20,836.00
      1.31%
      Dow Jones
      42,840.26
      1.18%
      Brent Oil
      72.72
      0.00%
      Bitcoin
      96,980.63
      -0.23%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Gilead Sciences Inc (GILD) Quote

      Gilead Sciences Inc

      Gilead Sciences Inc (GILD)

      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      Guild Esports Plc
      92.57
      1.48
      (1.62%)
      Closed December 22 4:00PM
      Delayed by 15 minutes
      92.56
      -0.01
      (-0.01%)
      After Hours: 7:48PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      92.56
      Bid
      84.93
      Ask
      93.49
      Volume
      22,525,936
      90.71 Day's Range 93.29
      62.07 52 Week Range 98.90
      Market Cap
      115.354B
      Previous Close
      91.09
      Open
      90.92
      Last Trade
      100
      @
      92.56
      (formt)
      Last Trade Time
      Financial Volume
      $ 2,085,956,006
      VWAP
      92.6024
      Average Volume (3m)
      6,398,399
      Shares Outstanding
      1,246,265,857
      Dividend Yield
      3.33%
      PE Ratio
      20.36
      Earnings Per Share (EPS)
      4.55
      Revenue
      27.12B
      Net Profit
      5.67B

      About Gilead Sciences Inc

      Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.gilead.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GILD. The last closing price for Gilead Sciences was $91.09. Over the last year, Gilead Sciences shares have traded in a share price range of $ 62.07 to $ 98.90.

      Gilead Sciences currently has 1,246,265,857 shares outstanding. The market capitalization of Gilead Sciences is $113.52 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 20.36.

      Ask ADVFN Intelligence (AI)

      Gilead Sciences (GILD) Options Flow Summary

      GILD Options Flow

      Overall Flow

      Bullish

      Net Premium

      24k

      Calls / Puts

      200.00%

      Buys / Sells

      100.00%

      OTM / ITM

      200.00%

      Sweeps Ratio

      0.00%

      GILD Latest News

      More News

      Gilead Sciences to Present at Upcoming Investor Conference

      Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025...

      December 20 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      December 19 2024
      Edgar (US Regulatory)

      Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      December 19 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 17 2024
      Edgar (US Regulatory)

      U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

      Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for...

      December 17 2024
      Business Wire

      Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

      -- Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest -- -- Gilead Has Exclusive Option to Develop and...

      December 17 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      December 16 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      December 16 2024
      Edgar (US Regulatory)

      Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

      – Recommendation Based on the RESPONSE Study Which Demonstrated ALP Normalization in 25% of Participants at 12 Months and Statistically Significant Reduction of Pruritus Versus Placebo – – If...

      December 13 2024
      Business Wire

      Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

      Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior...

      December 12 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.90.9818895919791.6693.5989.15736971791.65929908CS
      42.723.0276046304589.8494.6589.15679835991.87095128CS
      129.3311.209900276383.2398.982.82639839990.11723022CS
      2627.5542.378095677665.0198.964.86687133681.9637154CS
      5212.916.193823750979.6698.962.07697038677.08199264CS
      15620.5628.55555555567298.957.165713484273.59186043CS
      26026.9741.119073029465.5998.956.56842969671.64752579CS

      GILD - Frequently Asked Questions (FAQ)

      What is the current Gilead Sciences share price?
      The current share price of Gilead Sciences is $ 92.56
      How many Gilead Sciences shares are in issue?
      Gilead Sciences has 1,246,265,857 shares in issue
      What is the market cap of Gilead Sciences?
      The market capitalisation of Gilead Sciences is USD 113.52B
      What is the 1 year trading range for Gilead Sciences share price?
      Gilead Sciences has traded in the range of $ 62.07 to $ 98.90 during the past year
      What is the PE ratio of Gilead Sciences?
      The price to earnings ratio of Gilead Sciences is 20.36
      What is the cash to sales ratio of Gilead Sciences?
      The cash to sales ratio of Gilead Sciences is 4.25
      What is the reporting currency for Gilead Sciences?
      Gilead Sciences reports financial results in USD
      What is the latest annual turnover for Gilead Sciences?
      The latest annual turnover of Gilead Sciences is USD 27.12B
      What is the latest annual profit for Gilead Sciences?
      The latest annual profit of Gilead Sciences is USD 5.67B
      What is the registered address of Gilead Sciences?
      The registered address for Gilead Sciences is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
      What is the Gilead Sciences website address?
      The website address for Gilead Sciences is www.gilead.com
      Which industry sector does Gilead Sciences operate in?
      Gilead Sciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MYSZMy Size Inc
      $ 4.2001
      (211.12%)
      		121.03M
      NVNINVNI Group Ltd
      $ 8.26
      (209.36%)
      		78.06M
      TPICTPI Composites Inc
      $ 2.45
      (100.82%)
      		34M
      ICGIntchains Group Ltd
      $ 8.77
      (88.60%)
      		527.94k
      HSDTHelius Medical Technologies Inc
      $ 0.884851
      (84.34%)
      		121.95M
      CYNCYNGN Inc
      $ 0.4603
      (-71.41%)
      		27.91M
      MTEMMolecular Templates Inc
      $ 0.1502
      (-57.09%)
      		8.75M
      PRFXPainReform Ltd
      $ 5.15
      (-53.85%)
      		2.94M
      GALTGalectin Therapeutics Inc
      $ 1.03
      (-48.50%)
      		9.27M
      BCABBioAtla Inc
      $ 0.6923
      (-41.82%)
      		6.25M
      EDBLEdible Garden AG Inc
      $ 0.24
      (65.06%)
      		354.32M
      APTOAptose Biosciences Inc
      $ 0.28
      (64.51%)
      		305.1M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.606999
      (6.49%)
      		292.16M
      NVDANVIDIA Corporation
      $ 134.70
      (3.08%)
      		287.21M
      PLTRPalantir Technologies Inc
      $ 80.55
      (8.54%)
      		277.63M

      GILD Discussion

      View Posts
      jondoeuk jondoeuk 3 weeks ago
      They now add an investigational HIV vaccine to its portfolio https://www.fiercebiotech.com/biotech/gilead-buys-hiv-vaccine-spanish-biotech-following-success-clinical-collab

      Data on the vaccine in combination with vesatolimod https://www.ddw-online.com/hiv-combination-regimen-could-lead-to-viral-remission-22215-202302/
      👍️0
      jondoeuk jondoeuk 3 weeks ago
      Based on recent data*, I would have thought that getting KITE-509 into the clinic (for GPC3+ solid tumours, not just 3L+ HCC) would be a priority.

      * https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019 https://www.nature.com/articles/s41586-024-08261-8
      👍️0
      fink fink 1 month ago
      CEO is talking now.
      The stock is selling off on great words.
      Go figure! 6month Prep shot is a game changer. Generics are already being made for third world nations. These guys are going to eradicate AIDS.

      They should be allowed to make a buck or two.
      I want $250 a share please, I've held it way too long.
      👍️0
      Monksdream Monksdream 2 months ago
      GILD, 10Q 11/6
      👍️0
      Monksdream Monksdream 2 months ago
      GILD a new 52 week high
      👍️0
      Monksdream Monksdream 2 months ago
      GILD new 52=week high
      👍️0
      jondoeuk jondoeuk 2 months ago
      Two years later, and here are some of my takeaways...

      - They know they need to expand into more (rural) areas and that might include pre-built clean rooms. Slides 21-26 show how difficult it is to drive uptake further. "Majority of future growth expected from establishing new ATC's in community." These centres need to establish new relationships with others for apheresis, local ER's for (CRS/ICANS) emergencies and even local freezer storage requirements, which is it's own thing. So much goes into treatment that has nothing to do with manufacturing.

      - Forgot ZUMA-12 data was that good. A 86% CR rate and 81% three-year survival from 1L patients. Not sure how to compare that to later line trials, but decades from now, let's hope we are at the point we treat this front line (vs SOC now). Kite said their COGS is
      👍️0
      jondoeuk jondoeuk 2 months ago
      ''There have been more than 250 HIV vaccine trials, most of them early-stage, looking at whether the vaccine is safe and whether we mount an immune response following vaccination. There have been very few vaccine trials—10 or so—that have advanced to the point of looking at efficacy. Of those, one showed 31% efficacy at 42 months. That was the most promising trial, but the efficacy fell off very quickly, and it was only 31% and only against clade B. Whether that would translate to the other clades is not clear.'' https://publichealth.jhu.edu/2022/why-dont-we-have-an-hiv-vaccine
      👍️0
      jondoeuk jondoeuk 2 months ago
      https://x.com/JackSha90859576/status/1847728103021281381
      👍️0
      TechandBio TechandBio 3 months ago
      Wants to go higher!

      $GILD
      👍️0
      Monksdream Monksdream 3 months ago
      GILD approaching a 52 week high
      👍️0
      north40000 north40000 3 months ago
      Featured on CNBC-TV this morning, 8:40 a.m. time frame.
      👍️0
      TechandBio TechandBio 5 months ago
      NICE!

      clutch stock with a disruptive cure prevention vaccine for HIV people would rather take 2 shots a year not to get HIV then taking oral pills for treatment!

      $GILD
      👍️0
      TechandBio TechandBio 5 months ago
      Adding shares and calls under $80..00

      HIV Cure Vaccine is a big deal data is incredible flawless. Oncology pipeline is building nicely.



      $GILD
      $GILD
      👍️0
      midastouch017 midastouch017 5 months ago
      Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

      https://finance.yahoo.com/news/compugen-announces-fda-clearance-ind-110000034.html

      FDA clearance triggers a $30 million milestone payment from Gilead
      👍️0
      Monksdream Monksdream 5 months ago
      GILD under $100
      👍️0
      TechandBio TechandBio 5 months ago
      Target is $100-$120 by Q2 2025

      $GILD
      👍️0
      TechandBio TechandBio 5 months ago
      HIV Prevention CURE Shot 2x a year

      Great growing oncology pipeline!

      my $80 vertical Calls from last week are looking golden!

      $GILD
      👍️0
      north40000 north40000 6 months ago
      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

      "Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"
      👍️0
      north40000 north40000 6 months ago
      How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.
      👍️0
      jondoeuk jondoeuk 7 months ago
      There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.
      👍️0
      jondoeuk jondoeuk 7 months ago
      A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems
      👍️0
      jondoeuk jondoeuk 7 months ago
      They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study
      👍️0
      jondoeuk jondoeuk 7 months ago
      ''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

      https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html
      👍️0
      jondoeuk jondoeuk 7 months ago
      The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

      Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

      ''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.
      👍️0
      jondoeuk jondoeuk 8 months ago
      The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution
      👍️0
      jondoeuk jondoeuk 9 months ago
      IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
      👍️0
      jondoeuk jondoeuk 9 months ago
      Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
      👍️0
      jondoeuk jondoeuk 9 months ago
      Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
      👍️0
      jondoeuk jondoeuk 9 months ago
      I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
      👍️0
      jondoeuk jondoeuk 9 months ago
      Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
      👍️0
      Monksdream Monksdream 11 months ago
      GILD new 52 week high
      👍️0
      jondoeuk jondoeuk 1 year ago
      Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

      It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
      👍️0
      jondoeuk jondoeuk 1 year ago
      Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

      There have been a number of these over the years, but nothing seems to come of them
      👍️0
      jondoeuk jondoeuk 1 year ago
      The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

      If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
      👍️0
      Greedy G Greedy G 1 year ago
      ~bought 9/22 $80 calls .08c
      👍️0
      jondoeuk jondoeuk 2 years ago
      Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595
      👍️0
      DewDiligence DewDiligence 2 years ago
      Why is an oral prodrug of Remdesivir anything to get excited about?
      👍️0
      jondoeuk jondoeuk 2 years ago
      Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html
      👍️0
      jondoeuk jondoeuk 2 years ago
      Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

      What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

      The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.
      👍️0
      fink fink 2 years ago
      Christmas sell off over, last day to lock in any paper tax loss. LOL

      Who’s losing money here?

      I think we start the trend back up into Q1
      👍️0
      fink fink 2 years ago
      It wants $90.
      I got a sell order in @88, but think it will continue up.
      Gilead is moving away from HIV and more into this cancer thingy.

      That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

      Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
      👍️0
      PennyPusher786 PennyPusher786 2 years ago
      It's at a 3 year high
      👍️0
      fung_derf fung_derf 2 years ago
      Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

      I_luv_cydy

      Re: fung_derf post# 3875

      Tuesday, May 19, 2020 2:32:23 PM

      Post#
      3878
      of 4839
      Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.
      👍️0
      fink fink 2 years ago
      Nice to see GILD over $80

      Wonder if I should trim some? It’s been eating chit pie for some time.
      Still don’t see why the spike.
      👍️0
      jondoeuk jondoeuk 2 years ago
      Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

      Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2
      👍️0
      Zeppo Zeppo 3 years ago
      Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
      👍️0
      DewDiligence DewDiligence 3 years ago
      GILD details why the purportedly-positive Trodelvy data from Mar 2022 weren’t:

      https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a “trend in improvement” means non-statsig. OS could conceivably turn statsig in a later data cut, but that’s pretty unlikely.

      The viewpoint in #msg-158260565 (from 2020) has not changed.
      👍️0
      mick mick 3 years ago
      Gilead Sciences Inc (GILD)
      59.77 ? -1.79 (-2.91%)
      Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
      Bid Ask Day's Range
      59.53 60.0 59.27 - 62.06
      GILD Detailed Quote
      👍️0
      jondoeuk jondoeuk 3 years ago
      ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.




      👍️0

      Your Recent History

      NASDAQ
      GILD
      Gilead Sciences
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads